Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia

Item Type:	Article
Title:	Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia
Creators Name:	Kayser, S. and Martínez-Cuadrón, D. and Rodriguez-Veiga, R. and Hänel, M. and Tormo, M. and Schäfer-Eckart, K. and Botella, C. and Stölzel, F. and Del Castillo, T.B. and Keller, U. and Rodriguez-Medina, C. and Held, G. and Amigo, M.L. and Schliemann, C. and Colorado, M. and Kaufmann, M. and Garcia, M.B. and Krause, S.W. and Görner, M. and Jost, E. and Steffen, B. and Zukunft, S. and Platzbecker, U. and Ho, A.D. and Baldus, C.D. and Serve, H. and Müller-Tidow, C. and Thiede, C. and Bornhäuser, M. and Montesinos, P. and Röllig, C. and Schlenk, R.F.
Abstract:	We retrospectively studied 97 AML patients with trisomy 19 (tris-19; median age at diagnosis 57 years; range, 17-83 years) treated between 2001 and 2019 within two multicenter study groups. Tris-19 occurred solely in 10 (10.5%), with additional abnormalities in non-complex karyotypes in 8 (8%) and within complex karyotypes in 79 (82%) patients. Altogether, karyotypes characterized by trisomies only were present in 27 (28%) patients. Data on response and outcome of intensively treated patients were available in 92 patients and median follow-up was 6.4 years (95%-CI, 2.9-9.0 years). Complete remission (CR) after induction therapy was achieved in 52% (n=48) and early death rate was 10% (n=9). Notably, patients with tris-19 as sole abnormality had a CR rate of 89%. An allogeneic hematopoietic stem cell transplantation (allo-HCT) was performed in 34 (35%) patients (CR, n=19; active disease, n=15). Five-year relapse-free and overall survival (OS) rates were 26% (95%-CI, 16-43%) and 20% (95%-CI, 13-31%), respectively. OS rates were significantly higher in patients with tris-19 as sole abnormality or within karyotypes characterized by trisomies only (P=0.05). An Andersen-Gill model including allo-HCT as a time dependent covariable on OS revealed tris-19 as sole abnormality or within karyotypes characterized by trisomies only as favorable factors (HR, 0.47; P=0.021); higher age at diagnosis had an adverse impact (10 years difference; HR, 1.29; P=0.002), whereas allo-HCT had no beneficial impact (OR, 1.45; P=0.21). In our cohort, patients with tris-19 as sole abnormality or within karyotypes characterized by trisomies only had a high CR rate and better clinical outcome.
Keywords:	Acute Myeloid Leukemia, Trisomy 19, Allogeneic Hematopoietic Cell Transplantation, Outcome
Source:	Haematologica
ISSN:	0390-6078
Publisher:	Ferrata Storti Foundation
Date:	23 February 2023
Official Publication:	https://doi.org/10.3324/haematol.2022.282127
PubMed:	View item in PubMed

Repository Staff Only: item control page